SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis

Ilias Bensouna, Valérie Caudwell, Sabah Kubab, Sandra Acquaviva, Agathe Pardon, Nathalie Vittoz, Dogan-Firat Bozman, Latifa Hanafi, Anne-Laure Faucon, Pierre Housset, Ilias Bensouna, Valérie Caudwell, Sabah Kubab, Sandra Acquaviva, Agathe Pardon, Nathalie Vittoz, Dogan-Firat Bozman, Latifa Hanafi, Anne-Laure Faucon, Pierre Housset

Abstract

Rationale & objective: Recent studies showed that antibody titers after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the dialysis population are diminished as compared with the general population, suggesting the possible value of a third booster dose. We characterized the humoral response after 3 doses of the BNT162b2 vaccine in patients treated with either maintenance hemodialysis (HD) or peritoneal dialysis (PD).

Study design: Case series.

Setting & participants: 69 French patients (38 HD and 31 PD) treated at a single center who received 3 doses of the BNT162b2 vaccine.

Findings: Humoral response was evaluated using plasma levels of anti-SARS-CoV-2 spike protein S1 immunoglobulin measured after the second dose and at least 3 weeks after the third dose of the BNT162b2 vaccine. Patients (median age 68 years [interquartile range (IQR), 53-76 years], 65% men) had a median anti-S1 antibody level of 284 [IQR, 83-1190] AU/mL after the second dose, and 7,554 [IQR, 2,268-11,736] AU/mL after the third dose. Three patients were nonresponders (anti-S1 antibody level < 0.8 AU/mL), and 12 were weak responders (anti-S1 antibody level 0.8-50 AU/mL) after the second vaccine dose. After the third dose, 1 of the 3 initial nonresponders produced anti-spike antibody, and all the 12 initial weak responders increased their antibody levels. Patients with a greater increase in anti-S1 antibody levels after a third dose had lower antibody levels after the second dose, and a longer time interval between the second and the third dose. Adverse events did not seem to be more common or severe after a third vaccine dose.

Limitations: Observational study, small sample size. Relationship between antibody levels and clinical outcomes is not well understood.

Conclusions: A third dose of the BNT162b2 vaccine substantially increased antibody levels in patients receiving maintenance dialysis and appeared to be as well tolerated as a second dose.

Keywords: Antibody levels; BNT162b2; anti-spike serology; coronavirus disease 2019 (COVID-19); dialysis; end-stage renal disease (ESRD); immune response; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); third booster dose; vaccine; vaccine adverse effects.

Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Study flowchart. Abbreviations: HD, hemodialysis; peritoneal dialysis.
Figure 2
Figure 2
Humoral response after the second and the third vaccine doses. Abbreviations: Ab, antibody; AU, arbitrary unit.
Figure 3
Figure 3
Anti-spike antibody increase after the third vaccine dose according to the delay between the second and the third vaccine doses, and anti-spike antibody level after the second vaccine dose. Abbreviation: Ab, antibody.
Figure 4
Figure 4
Self-reported (left panel) reactions to vaccine after the third dose and (right panel) overall tolerance of the third vaccine dose.

References

    1. Shimada N., Shimada H., Itaya Y., Tomino Y. Novel coronavirus disease in patients with end-stage kidney disease. Ther Apher Dial. 2021;25(5):544–550. doi: 10.1111/1744-9987.13599.
    1. Meziyerh S., Helm D., Vries A.P.J. Vulnerabilities in kidney transplant recipients with COVID-19: a single center experience. Transpl Int. 2020;33(11):1557–1561. doi: 10.1111/tri.13714.
    1. Nikoskelainen J., Koskela M., Forsström J., Kasanen A., Leinonen M. Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. Kidney Int. 1985;28(4):672–677. doi: 10.1038/ki.1985.182.
    1. Pitchou Y Kengibe, Jean-Robert R Makulo, Yannick M Nlandu, et al. Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study. Pan Afr Med J. 2019;34:122. doi: 10.11604/pamj.2019.34.122.19603.
    1. Crépin T., Legendre M., Courivaud C., et al. Premature immune senescence and chronic kidney disease: update and perspectives. Article in French. Nephrol Ther. 2020;16(1):9–18. doi: 10.1016/j.nephro.2019.04.005.
    1. Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577.
    1. Grupper A, Sharon N, Finn T, et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. Published online April 6, 2021.
    1. Ikizler T.A., Coates P.T., Rovin B.H., Ronco P. Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. Kidney Int. 2021;99(6):1275–1279. doi: 10.1016/j.kint.2021.04.007.
    1. Torreggiani M., Blanchi S., Fois A., Fessi H., Piccoli G.B. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won. Kidney Int. 2021;99(6):1494–1496. doi: 10.1016/j.kint.2021.04.010.
    1. Attias P., Sakhi H., Rieu P., et al. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Kidney Int. 2021;99(6):1490–1492. doi: 10.1016/j.kint.2021.04.009.
    1. Yanay N.B., Freiman S., Shapira M., et al. Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients. Kidney Int. 2021;99(6):1496–1498. doi: 10.1016/j.kint.2021.04.006.
    1. Agur T, Ben-Dor N, Goldman S, et al. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study. Nephrol Dial Transplant. Published online April 11, 2021.
    1. Simon B, Rubey H, Treipl A, et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls. Nephrol Dial Transplant. Published online May 17, 2021.
    1. Centre opérationnel de régulation et de réponse aux urgences sanitaires et sociales (CORRUSS) DGS-Urgent No. 2021-43. Vaccins contre la Covid-19: modalites d’administration des rappels. April 11, 2021.
    1. Werbel W.A., Boyarsky B.J., Ou M.T., et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med. 2021;174(9):1330–1332. doi: 10.7326/L21-0282.
    1. Kamar N., Abravanel F., Marion O., Couat C., Izopet J., Del Bello A. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661–662. doi: 10.1056/NEJMc2108861.
    1. Frantzen L, Thibeaut S, Moussi-Frances J, et al. COVID-19 Vaccination in haemodialysis patients: good things come in threes. Nephrol Dial Transplant. Published online July 20, 2021.
    1. Mueller T. Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: a method comparison of two different commercially available serological assays from the same manufacturer. Clin Chim Acta. 2021;518:9–16. doi: 10.1016/j.cca.2021.03.007.
    1. Bird S., Panopoulou A., Shea R.L., et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021;8(6):e389–e392. doi: 10.1016/S2352-3026(21)00110-1.
    1. Sakhi H., Dahmane D., Attias P., et al. Kinetics of anti–SARS-CoV-2 IgG antibodies in hemodialysis patients six months after infection. J Am Soc Nephrol. 2021;32(5):1033–1036. doi: 10.1681/ASN.2020111618.
    1. Clarke C.L., Prendecki M., Dhutia A., et al. Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. Kidney Int. 2021;99(6):1470–1477. doi: 10.1016/j.kint.2021.03.009.
    1. Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. Published online July 20, 2021.
    1. Lumley S.F., O’Donnell D., Stoesser N.E., et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2020;384(6):533–540. doi: 10.1056/NEJMoa2034545.
    1. Joyner M.J., Carter R.E., Senefeld J.W., et al. Convalescent plasma antibody levels and the risk of death from COVID-19. N Engl J Med. 2021;384(11):1015–1027. doi: 10.1056/NEJMoa2031893.
    1. Broseta J.J., Rodríguez-Espinosa D., Rodríguez N., et al. Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients. Am J Kidney Dis. 2021;78(4):571–681.
    1. Hu Y., Xu L., Wang X., et al. Changes before and after COVID-19 pandemic on the personal hygiene behaviors and incidence of peritonitis in peritoneal-dialysis patients: a multi-center retrospective study. Int Urol Nephrol. Published online June 19, 2021 doi: 10.1007/s11255-021-02924-5.
    1. Day M. COVID-19: Stronger warnings are needed to curb socialising after vaccination, say doctors and behavioural scientists. BMJ. 2021;372:n783. doi: 10.1136/bmj.n783.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere